Organigram Global Inc.: Organigram Reports Record Third Quarter Fiscal 2026 Results
Organigram Global Inc. (NASDAQ: OGI) reported Q3 fiscal 2026 results for the quarter ended June 30, 2026. Gross revenue rose 32% to $145.1M, net revenue increased 49% to $105.8M, and adjusted EBITDA climbed 136% to $13.4M, driven largely by its April 15, 2026 acquisition of Sanity Group. The company expects FY net revenue over $350M.
How this was made
The 30-second read
Why it matters
Investors get acquisition contribution detail (Sanity net revenue contribution since April 15, 2026) plus quarterly financial performance and a stated FY2026 outlook framework (net revenue > $350m; positive FCF expected in Q4).
Market read
This is a primary earnings release with record quarterly revenue and adjusted EBITDA, plus margin and cash-flow details that can drive repricing and positioning ahead of the Q4 cash-generation narrative.
What to watch
Liquidity is limited (cash $11.7m, total liquidity $49.1m including credit facilities), and net income includes non-cash fair value gains on preferred shares, which may overstate underlying earnings quality.
Background
Organigram is a Canadian cannabis company expanding globally after acquiring Sanity Group, with this release covering Q3 ended June 30, 2026.
Ticker impact
Organigram reported Q3 FY2026 results with net revenue up 49% and adjusted EBITDA up 136%, driven by Sanity Group contributions.
Near-term bias positive on earnings momentum, but expect volatility as investors weigh growth versus cash burn and modest liquidity.
The release provides concrete quarterly datapoints (revenue, adjusted EBITDA, gross margin, FCF) and a forward-looking statement about FY2026 net revenue and positive FCF in Q4, which can re-rate expectations while cash metrics temper enthusiasm.
Market effects
Cannabis peers may see read-across on acquisition integration and international expansion execution, especially in Europe.
Canadian market leadership claims and improved Canadian operational efficiencies could influence sentiment toward Canadian cannabis operators.
European growth progress via Sanity Group (Switzerland, Poland, UK) supports the narrative of cross-border scaling in regulated cannabis markets.
Counterpoint
Despite record EBITDA, free cash flow was still negative and cash plus short-term investments fell sharply versus Sept 30, 2025, suggesting growth may be working-capital intensive.
Key entities
- companyOrganigram Global Inc.
NASDAQ-listed cannabis company reporting Q3 FY2026 results and acquisition-driven growth.
- companySanity Group GmbH
European cannabis platform acquired by Organigram, contributing approximately €25m (C$40m) net revenue in the quarter.
- personJames Yamanaka
CEO quoted on record quarterly results and integration progress.
- personGreg Guyatt
CFO quoted on outlook and free cash flow expectations for Q4.
